相关实验视频

Updated: Jul 26, 2025

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

新药组合治疗方案在复发性/耐药性多发性骨髓瘤上的比较疗效:一个网络元分析

Haimin Chen¹, Haiqi Chen², Yan Zhou¹

¹Department of Hematology and Oncology, Zhabei Central Hospital, Shanghai, People's Republic of China.

Hematology (Amsterdam, Netherlands)

|June 21, 2023

概括

对复发性和耐火性多发性骨髓瘤 (RRMM) 的新型治疗方法的有效性各不相同. 在RRMM患者中,基于达拉图穆马布和伊萨图キシ马布的疗法提供了比其他新药组合更高的响应率.

科学领域:

血液学血液学血液学
在瘤学瘤学.
临床试验和治疗方法

背景情况:

多发性骨髓瘤仍然无法治愈,但针对复发性和耐药性病例 (RRMM) 正在出现新的治疗方法.
关于这些新型RRMM治疗方法的疗效的直接比较数据有限.
评估治疗有效性对于优化RRMM患者的治疗结果至关重要.

研究的目的:

进行网络元分析,比较RRMM的新药疗法.
评估即时治疗效果,重点关注反应质量.
确定RRMM最有效的新型治疗方案.

主要方法:

在Cochrane图书馆,PubMed,Embase和Web of Science系统搜索相关的随机对照试验 (RCT).
主要终点:客观反应率 (ORR).
13种新型药物方案的分类和使用积累性排名曲线下的表面 (SUCRA) 进行治疗序列.

主要成果:

基于carfilzomib,daratumumab和isatuximab的疗法显示ORR优于博尔特佐米布/德甲和莱纳利多米德/德甲.
基于达拉图穆马布和伊萨图西马布的疗法显示了比波马利多米德/德克萨米他更好的ORR.
SUCRA的排名显示,基于达拉图穆马布和伊萨图西马布的三重药物疗法是高ORR最有前途的.

结论:

这个网络元分析提供了对RRMM新药疗程的全面审查.
基于达拉图穆马布和伊萨图キシ马布的治疗方法被确定为最有效的,产生更好的反应质量.
这些发现支持在RRMM治疗策略中使用基于达拉图穆马布和伊萨图キシ马布的疗法.

关键词:

复发性或耐火性多发性骨髓瘤网络元分析网络元分析整体响应率的整体响应率.

更多相关视频

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...